Reports
Reports
Sale
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Granulomatosis with Polyangiitis Treatment Market Overview – 8 Major Markets
3.1 Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
3.2 Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
4 Granulomatosis with Polyangiitis Treatment Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Granulomatosis with Polyangiitis Treatment Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.1.1 Prevalence, by Country
6.1.1.1 U.S.
6.1.1.2 U.K.
6.1.1.3 EU4
6.1.1.4 India
6.1.1.5 Japan
6.1.2 Mortality, by Country
6.1.2.1 U.S.
6.1.2.2 U.K.
6.1.2.3 EU4
6.1.2.4 India
6.1.2.5 Japan
6.1.3 Treatment seeking rate, by Country
6.1.3.1 U.S.
6.1.3.2 U.K.
6.1.3.3 EU4
6.1.3.4 India
6.1.3.5 Japan
7 Granulomatosis with Polyangiitis Treatment Market Landscape – 8 Major Markets
7.1 Granulomatosis with Polyangiitis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Granulomatosis with Polyangiitis Treatment: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Route of Administration
8 Granulomatosis with Polyangiitis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Granulomatosis with Polyangiitis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 PESTEL Analysis
10.3.1 Political
10.3.2 Economic
10.3.3 Social
10.3.4 Technological
10.3.5 Legal
10.3.6 Environment
10.4 Porter’s Five Forces Model
10.4.1 Bargaining Power of Suppliers
10.4.2 Bargaining Power of Buyers
10.4.3 Threat of New Entrants
10.4.4 Threat of Substitutes
10.4.5 Degree of Rivalry
10.5 Key Demand Indicators
10.6 Key Price Indicators
10.7 Industry Events, Initiatives, and Trends
10.8 Value Chain Analysis
11 Granulomatosis with Polyangiitis Treatment Market Segmentation (2017-2032) - 8 Major Markets
11.1 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
11.1.1 Market Overview
11.1.2 Steroids
11.1.2.1 Prednisolone
11.1.2.2 Dexamethasone
11.1.2.3 Others
11.1.3 Immunosuppressant
11.1.3.1 Cyclosporine
11.1.3.2 Tacrolimus
11.1.3.3 Sirolimus
11.1.3.4 Others
11.1.4 Others
11.2 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Injectable
11.2.4 Others
11.3 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
11.3.1 Market Overview
11.3.2 Prescription
11.3.3 Over the Counter
11.4 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
11.4.1 Market Overview
11.4.2 Male
11.4.3 Female
11.5 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Home Healthcare
11.5.5 Others
11.6 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Retail Pharmacies
11.6.4 Others
11.7 Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
11.7.5 India
12 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032)
12.1 United States Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
12.2 United States Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
12.3 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
12.3.1 Market Overview
12.3.2 Steroids
12.3.2.1 Prednisolone
12.3.2.2 Dexamethasone
12.3.2.3 Others
12.3.3 Immunosuppressant
12.3.3.1 Cyclosporine
12.3.3.2 Tacrolimus
12.3.3.3 Sirolimus
12.3.3.4 Others
12.3.4 Others
12.4 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Injectable
12.4.4 Others
12.5 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
12.5.1 Market Overview
12.5.2 Prescription
12.5.3 Over the Counter
12.6 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
12.6.1 Market Overview
12.6.2 Male
12.6.3 Female
12.7 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
12.7.1 Market Overview
12.7.2 Hospitals
12.7.3 Specialty Clinics
12.7.4 Home Healthcare
12.7.5 Others
12.8 United States Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
12.8.1 Market Overview
12.8.2 Hospital Pharmacies
12.8.3 Retail Pharmacies
12.8.4 Others
13 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032)
13.1 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
13.3.1 Market Overview
13.3.2 Steroids
13.3.2.1 Prednisolone
13.3.2.2 Dexamethasone
13.3.3 Immunosuppressant
13.3.3.1 Cyclosporine
13.3.3.2 Tacrolimus
13.3.3.3 Sirolimus
13.3.4 Others
13.4 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Injectable
13.4.4 Others
13.5 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
13.5.1 Market Overview
13.5.2 Prescription
13.5.3 Over the Counter
13.6 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
13.6.1 Market Overview
13.6.2 Male
13.6.3 Female
13.7 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
13.7.1 Market Overview
13.7.2 Hospitals
13.7.3 Specialty Clinics
13.7.4 Home Healthcare
13.7.5 Others
13.8 EU-4 and United Kingdom Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
13.8.1 Market Overview
13.8.2 Hospital Pharmacies
13.8.3 Retail Pharmacies
13.8.4 Others
14 Japan Granulomatosis with Polyangiitis Treatment Market
14.1 Japan Granulomatosis with Polyangiitis Treatment Market Historical Value (2017-2023)
14.2 Japan Granulomatosis with Polyangiitis Treatment Market Forecast Value (2024-2032)
14.3 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
14.3.1 Market Overview
14.3.2 Steroids
14.3.2.1 Prednisolone
14.3.2.2 Dexamethasone
14.3.2.3 Others
14.3.3 Immunosuppressant
14.3.3.1 Cyclosporine
14.3.3.2 Tacrolimus
14.3.3.3 Sirolimus
14.3.3.4 Others
14.3.4 Others
14.4 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Injectable
14.4.4 Others
14.5 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
14.5.1 Market Overview
14.5.2 Prescription
14.5.3 Over the Counter
14.6 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
14.6.1 Market Overview
14.6.2 Male
14.6.3 Female
14.7 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
14.7.1 Market Overview
14.7.2 Hospitals
14.7.3 Specialty Clinics
14.7.4 Home Healthcare
14.7.5 Others
14.8 Japan Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
14.8.1 Market Overview
14.8.2 Hospital Pharmacies
14.8.3 Retail Pharmacies
14.8.4 Others
15 India Granulomatosis with Polyangiitis Treatment Market
15.1 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Historical Value (2017-2023)
15.2 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) Forecast Value (2024-2032)
15.3 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Drug Type
15.3.1 Market Overview
15.3.2 Steroids
15.3.2.1 Prednisolone
15.3.2.2 Dexamethasone
15.3.2.3 Others
15.3.3 Immunosuppressant
15.3.3.1 Cyclosporine
15.3.3.2 Tacrolimus
15.3.3.3 Sirolimus
15.3.3.4 Others
15.3.4 Others
15.4 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Injectable
15.4.4 Others
15.5 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Mode of Purchase
15.5.1 Market Overview
15.5.2 Prescription
15.5.3 Over the Counter
15.6 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Gender
15.6.1 Market Overview
15.6.2 Male
15.6.3 Female
15.7 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by End User
15.7.1 Market Overview
15.7.2 Hospitals
15.7.3 Specialty Clinics
15.7.4 Home Healthcare
15.7.5 Others
15.8 India Granulomatosis with Polyangiitis Treatment Market (2017-2032) by Distribution Channel
15.8.1 Market Overview
15.8.2 Hospital Pharmacies
15.8.3 Retail Pharmacies
15.8.4 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 Genentech, Inc. (A subsidiary of F. Hoffman-La Roche Ltd)
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 GlaxoSmithKline plc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Teva Pharmaceutical Industries Ltd.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Pfizer Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Actiza Pharma
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Sun Pharmaceutical Industries Ltd.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Janssen Pharmaceutical, Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Novartis AG
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Sanofi
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
23 Granulomatosis with Polyangiitis Treatment Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.